[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Next Biomedical Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":129},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,40,64,86,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100587614","study-in-patients-with-knee-osteoarthritis-treated-by-embolization-using-nbgm200-100587614",false,"NCT06930677","Study in Patients With Knee Osteoarthritis Treated by Embolization Using NBGM200","A Prospective, Single-arm, Multinational, Multi-center, Clinical Study to Evaluate the Performance and Safety of Musculoskeletal Embolization Using NBGM200 in Patients With Knee Degenerative Osteoarthritis","Inclusion Criteria:\n\n* Osteoarthritis proven by MR-imaging\n\nExclusion Criteria:\n\n* Current local infection\n* Life expectancy less than 6 months","ALL","50 Years",{"count":19,"type":20},72,"ESTIMATED","INTERVENTIONAL",[23],"NA","Study in patients with knee osteoarthritis treated by embolization using NBGM200",[26],"Knee Osteoarthritis (Knee OA)","RECRUITING","2025-11-17",{"date":30,"type":31},"2025-11-19","ACTUAL",{"date":33,"type":31},"2025-04-17",{"date":35,"type":20},"2027-02",{"name":37,"class":38},"Next Biomedical Co., Ltd.","INDUSTRY",3,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":44,"conditions":51,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100588323","clinical-trial-to-evaluate-the-efficacy-and-safety-of-nexpowder-for-diverticular-bleeding-in-the-lower-gastrointestinal-tract-100588323","NCT06939907","Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract","Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract: A Prospective, Multi-Center, Single-Arm, Open-Label, Pilot Clinical Trial","Inclusion Criteria:\n\n* Adults aged 19 years or older at the time of screening\n* Patients diagnosed with diverticular bleeding\n\nExclusion Criteria:\n\n* Patients diagnosed with upper gastrointestinal bleeding","19 Years",{"count":49,"type":20},60,[23],[52,53],"Lower Gastrointestinal Bleeding","Diverticular Bleeding","NOT_YET_RECRUITING","2025-04-24",{"date":57,"type":31},"2025-04-25",{"date":59,"type":20},"2025-06",{"date":61,"type":20},"2027-07",{"name":37,"class":38},6,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},"100509714","transcatheter-arterial-micro-embolization-tame-using-nexsphere-f-in-patients-with-knee-degenerative-osteoarthritis-100509714","NCT05917028","Transcatheter Arterial Micro-Embolization (TAME) Using Nexsphere-F in Patients With Knee Degenerative Osteoarthritis","A Single Arm, Single Center, Open Label , Pilot Clinical Study to Evaluate the Efficacy and Safety of Transcatheter Arterial Micro Embolization (TAME) Using Nexsphere F in Patients With Knee Degenerative Osteoarthritis","Inclusion Criteria:\n\n* Those who fall under Kellgren-Lawrence grade 2 to 3 according to the criteria in accordance with ACR guidelines and X-ray findings used within 12 months\n* VAS score exceeding 50mm\n* An adult male and female over 50 years of age\n* Preservative therapy Glucosamine chondroitin sulfate\u002Fphysiological therapy and rehabilitation exercises, and joint injections of hyaluronic acid for more than 12 weeks\n* A person who agrees to maintain existing medication treatments during the clinical trial period but does not receive additional medication or new conservative treatments for knee osteoarthritis pain management.\n\nExclusion Criteria:\n\n* A locally infected patient\n* A person whose life expectancy is less than six months\n* A person with symptoms of lower extremities that are considered secondary to atherosclerosis or arterial vascular disease (ex: claudication ischemic rest pain)\n* A person diagnosed with rheumatism or infectious arthritis\n* A person who has undergone knee arthroplasty\n* A person who has not had knee microfracture surgery for more than 10 years\n* INR 2.5 or less than 30,000 platelets\n* Anaphylaxis-causing iodine allergy\n* Patients with renal dysfunction or impaired renal function who have been diagnosed with less than 45 GFR (eGFR) within the last 60 days\n* Those who have a taboo on MR videos\n* Pregnant women\n* Other cases where it is deemed inappropriate to participate in this clinical trial at the discretion of the researcher",{"count":72,"type":20},20,[23],"Among knee degenerative osteoarthritis patients aged 50 or older, it will prove the therapeutic effect and safety of Nexsphere-F embolization for patients who need additional treatment because pain is not controlled even if conventional treatments are taken.",[76],"Osteoarthritis","2025-03-27",{"date":79,"type":31},"2025-04-02",{"date":81,"type":31},"2023-10-23",{"date":83,"type":20},"2025-12",{"name":37,"class":38},1,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":21,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":85},"100444792","safety-and-efficacy-of-degradable-microsphere-in-transcatheter-arterial-chemoembolization-for-hepatocellular-carcinoma-100444792","NCT05072041","Safety and Efficacy of Degradable Microsphere in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma","Safety and Efficacy of Degradable Microsphere in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: a Prospective Comparative Study","Inclusion Criteria:\n\n1. Adult patients aged 19 to 79 years\n2. Patient who signed Informed Consent Form\n3. Patients diagnosed with hepatocellular carcinoma by American Association for the Study of Liver Diseases (AASLD) and at least one of the following methods i. Magnetic resonance imaging (MRI) with early augmentation and delayed excretion of at least one solid liver lesion greater than 1 ㎝.\n\n   ii. Contrast-enhanced computed tomography (CT) with early augmentation and delayed build-up of at least one solid liver lesion \\>1 ㎝.\n\n   iii. Lesions with inconclusive features require histological confirmation.\n4. Patients should not be eligible for treatment by amputation or percutaneous resection or liver transplantation at the time of study enrollment.\n\n   i. Patients who are not suitable for ablation due to lesion location may be enrolled.\n\n   ii. Patients with recurrent hepatocellular carcinoma who are not suitable for amputation or resection may be enrolled.\n5. Must be Child-Pugh A or B hepatocellular carcinoma, and must satisfy the following criteria.\n\n   i. Tumor lesion size from 1 ㎝ to 10 ㎝ ii. Number of tumors 1-7 iii. Physical activity European Cooperative Oncology Group (ECOG) ≤ 1 without vascular involvement\n6. Patients who can be followed up until the end of the study and whose life expectancy is 6 months or longer\n\nExclusion Criteria:\n\n1. Patients under the age of 19\n2. Chronic kidney disease (CDK) grade 4 or 5 patients\n3. Current or previous treatment with chemotherapy or radiation therapy or sorafenib or drug release chemoembolization (deTACE) after diagnosis of hepatocellular carcinoma\n\n5\\. Pregnant, lactating, pre-menopausal and women not using effective contraceptive methods 6. Performance state European Cooperative Oncology Group (ECOG) \\> 1 7. Child-Poo Class C 8. Advanced hepatocellular carcinoma with vascular invasion or extrahepatic metastasis 9. Active Gastrointestinal Bleeding 10. Evidence of irreversible bleeding constitution 11. Encephalopathy that is not medically adequately controlled 12. Presence of ascites that is not medically controlled 13. Contraindications to Magnetic Resonance Imaging or Computed Tomography scan (e.g. metal implants) 14. Allergy to contrast media that cannot be managed by prevention 15. Contraindications to angiography 16. Contraindications to the administration of cisplatin anticancer drugs 17. Contraindications to hepatic artery embolization\n\n* Extensive context-to-systemic shunts\n* hepatofugal portal blood flow\n* Serum bilirubin \\> 3.0 ㎎\u002FdL\n* Serum creatinine \\> 2.0 ㎎\u002FdL\n* Other symptoms that your doctor has determined to be exclusive.\n* Irreversible blood clotting disorders 18. Others who are judged to be difficult for the principal investigator or principal investigator to conduct this clinical trial for other reasons","79 Years",{"count":95,"type":20},150,[23],"The purpose of this study was to prospectively collect clinical data from patients who underwent hepatic artery chemoembolization using microspheres with different degradation times (2 hours, 1 day, 2 weeks) based on standard treatment.",[99],"Hepatocellular Carcinoma","2024-11-12",{"date":102,"type":31},"2024-11-14",{"date":104,"type":31},"2021-10-31",{"date":106,"type":20},"2025-12-31",{"name":37,"class":38},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":21,"phases":118,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":85},"100532057","transcatheter-arterial-micro-embolization-tame-using-nexsphere-f-in-patients-with-chronic-pain-in-elbow-or-wrist-100532057","NCT06207851","Transcatheter Arterial Micro-Embolization (TAME) Using Nexsphere-F in Patients With Chronic Pain in Elbow or Wrist","A Single-arm, Single-center, Open-label, Pilot Clinical Study to Evaluate the Efficacy and Safety of Transcatheter Arterial Micro-Embolization (TAME) Using Nexsphere-F in Patients With Chronic Pain in Elbow or Wrist","Inclusion Criteria:\n\n1. Those aged 19 to 80\n2. Anyone who can provide a consent form\n3. A person with a life expectancy of at least 12 months\n4. Those who have not responded or failed in preservation treatment for at least three months(e.g. NSAIDS\u002Fphysical therapy\u002Fsteroidal joint injections, etc.)\n5. VAS score of 4 or higher and moderate-severe elbow or wrist pain\n\nExclusion Criteria:\n\n1. Those with a VAS Score of less than 4 and Mild Elbow or Wrist Pain\n2. Chronic Renal Insufficiency(Serum creatinine \\> 2mg\u002FdL)\n3. allergy to iodide contrast agents that do not respond to steroids\n4. Those with acute infection or malignancy\n5. Those who have previously had elbow or wrist surgery\n6. Those with Bleeding Diabetes that cannot be calibrated","80 Years",{"count":117,"type":20},38,[23],"In patients with chronic elbow or wrist pain, the pain is controlled by conventional conservative therapy The pain reduction effect of Nexsphere-F embolization in patients who need additional treatment It is intended to demonstrate safety.",[76],"2024-03-21",{"date":123,"type":31},"2024-03-25",{"date":125,"type":31},"2023-07-13",{"date":127,"type":20},"2026-07-13",{"name":37,"class":38},""]